在双重抗HER2阻塞下,HER2过度表达乳腺癌的免疫微环境动态
Sofia Batalha1,2, Catarina Monteiro Gomes1,2, Catarina Brito1,2
1iBET, Instituto de Biologia Experimental e Tecnológica, Oeiras, Portugal.
Frontiers in immunology
|November 29, 2023
概括
这项研究开发了一个3D模型来研究免疫细胞对针对HER2的乳腺癌疗法的反应. 该模型表明,双抗体治疗增强NK细胞活性和瘤细胞死亡,为改善治疗策略提供了见解.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 生物技术是生物技术.
背景情况:
- HER2过度表达乳腺癌 (BC) 的预后与瘤免疫透有关.
- 单细胞细胞促进免疫抑制,而NK细胞可以在治疗上得到增强.
- 目前的抗HER2抗体组合,如trastuzumab和pertuzumab可以改善结果,但并不能使所有患者受益,因此需要进一步研究他们的免疫机制.
研究的目的:
- 研究双抗HER2抗体治疗对免疫细胞的表型和功能在HER2过度表达的BC微环境中的影响.
- 开发和验证一种新的体外3D模型,用于研究这些免疫动态.
主要方法:
- 使用HER2+BC细胞系和人类外周血液单核细胞开发3D异型细胞模型.
- 在酸盐水凝中与优化培养条件 (时间,细胞因子) 一起封装,长达7天.
- 具有挑战性的模型与标准护理的抗HER2抗体 (trastuzumab和pertuzumab).
主要成果:
- 3D模型成功地保留了BC分子特征和NK细胞群.
- 双重抗体治疗 (特拉斯图祖马布+珀图祖马布) 与单独使用特拉斯图祖马布相比显著增强了免疫细胞毒性.
- 治疗诱导了免疫效应状态,包括NK细胞激活,增加瘤细胞亡,减少免疫抑制PD-L1+细胞.
结论:
- 为研究抗HER2生物制剂的免疫调节作用,建立了一个独特的人体3D模型.
- 这种模型可以促进新型治疗方案的测试.
- 这些发现为改善HER2+BC的抗瘤免疫功能提供了基础.
关键词:
3D细胞模型 3D细胞模型在HER2+乳腺癌中,HER2+是乳腺癌的基因.在 NK 细胞中,NK 细胞是 NK 细胞.免疫反应的免疫反应.免疫疗法 免疫疗法皮尔图祖马布 (pertuzumab) 的使用情况这就是特拉斯图祖马布 (trastuzumab).瘤微环境是一个微环境.更多相关视频
相关概念视频
02:17The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
02:38Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K